John Morton
Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 10 | 2023 | 562 | 1.200 |
Why?
| | Bariatric Surgery | 6 | 2025 | 242 | 1.200 |
Why?
| | Immunotherapy | 2 | 2020 | 657 | 0.900 |
Why?
| | Gastric Bypass | 3 | 2024 | 125 | 0.860 |
Why?
| | Xenograft Model Antitumor Assays | 9 | 2020 | 930 | 0.800 |
Why?
| | Disease Models, Animal | 6 | 2020 | 4569 | 0.680 |
Why?
| | Neoplastic Stem Cells | 6 | 2020 | 412 | 0.650 |
Why?
| | Caenorhabditis elegans | 4 | 2013 | 337 | 0.630 |
Why?
| | Tumor Microenvironment | 4 | 2020 | 735 | 0.600 |
Why?
| | Carcinoma, Squamous Cell | 7 | 2019 | 642 | 0.570 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2018 | 59 | 0.540 |
Why?
| | Hematopoietic Stem Cells | 2 | 2018 | 420 | 0.520 |
Why?
| | RNA, Helminth | 3 | 2013 | 18 | 0.440 |
Why?
| | Laparoscopy | 1 | 2019 | 475 | 0.430 |
Why?
| | Transcription Initiation Site | 2 | 2013 | 43 | 0.420 |
Why?
| | Operon | 2 | 2011 | 69 | 0.410 |
Why?
| | Melanoma | 1 | 2020 | 761 | 0.400 |
Why?
| | Obesity, Morbid | 3 | 2024 | 281 | 0.400 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 676 | 0.370 |
Why?
| | Trans-Splicing | 2 | 2013 | 12 | 0.360 |
Why?
| | Thymus Gland | 2 | 2023 | 311 | 0.340 |
Why?
| | DNA, Recombinant | 1 | 2010 | 48 | 0.330 |
Why?
| | Postoperative Nausea and Vomiting | 2 | 2021 | 25 | 0.330 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2011 | 92 | 0.310 |
Why?
| | Mice | 17 | 2023 | 18365 | 0.300 |
Why?
| | Animals | 23 | 2023 | 38109 | 0.270 |
Why?
| | Transplantation, Heterologous | 2 | 2018 | 194 | 0.250 |
Why?
| | Neoplasms | 2 | 2020 | 2884 | 0.220 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1982 | 0.210 |
Why?
| | Genes, Helminth | 3 | 2013 | 30 | 0.200 |
Why?
| | Immunophenotyping | 3 | 2019 | 322 | 0.190 |
Why?
| | Metabolic Diseases | 1 | 2024 | 114 | 0.190 |
Why?
| | Hyaluronan Receptors | 2 | 2020 | 102 | 0.190 |
Why?
| | Hedgehog Proteins | 2 | 2014 | 197 | 0.190 |
Why?
| | Acarbose | 1 | 2022 | 2 | 0.190 |
Why?
| | Consensus | 2 | 2025 | 489 | 0.190 |
Why?
| | Pluripotent Stem Cells | 1 | 2023 | 84 | 0.180 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 241 | 0.170 |
Why?
| | Sirolimus | 1 | 2022 | 281 | 0.160 |
Why?
| | SOXB1 Transcription Factors | 2 | 2020 | 67 | 0.160 |
Why?
| | Humans | 27 | 2025 | 144957 | 0.160 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 48 | 0.150 |
Why?
| | Radiotherapy Dosage | 2 | 2020 | 289 | 0.150 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 252 | 0.150 |
Why?
| | Stem Cell Niche | 1 | 2019 | 58 | 0.150 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 90 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2025 | 2584 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 276 | 0.140 |
Why?
| | Peptides, Cyclic | 1 | 2020 | 275 | 0.140 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 39 | 0.130 |
Why?
| | RNA, Messenger | 3 | 2016 | 2832 | 0.130 |
Why?
| | Mice, Nude | 5 | 2018 | 688 | 0.130 |
Why?
| | Veratrum Alkaloids | 2 | 2014 | 20 | 0.130 |
Why?
| | Cell Differentiation | 4 | 2023 | 2050 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2013 | 988 | 0.120 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2016 | 25 | 0.120 |
Why?
| | Cell Communication | 1 | 2018 | 324 | 0.120 |
Why?
| | Cell Proliferation | 4 | 2019 | 2499 | 0.120 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 210 | 0.120 |
Why?
| | ErbB Receptors | 3 | 2016 | 629 | 0.120 |
Why?
| | Disease Management | 1 | 2020 | 647 | 0.120 |
Why?
| | Telomere | 1 | 2019 | 288 | 0.120 |
Why?
| | Mice, Knockout | 3 | 2018 | 3125 | 0.120 |
Why?
| | Radiometry | 1 | 2015 | 57 | 0.120 |
Why?
| | Cell Line, Tumor | 6 | 2020 | 3550 | 0.110 |
Why?
| | Radiotherapy, Conformal | 1 | 2015 | 74 | 0.110 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 149 | 0.110 |
Why?
| | Neoplasms, Experimental | 1 | 2015 | 173 | 0.110 |
Why?
| | Stromal Cells | 1 | 2014 | 125 | 0.100 |
Why?
| | Mice, Inbred NOD | 3 | 2023 | 610 | 0.100 |
Why?
| | Radiation Tolerance | 1 | 2014 | 103 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 2 | 2014 | 675 | 0.100 |
Why?
| | Base Sequence | 3 | 2013 | 2191 | 0.100 |
Why?
| | Obesity | 3 | 2024 | 3082 | 0.090 |
Why?
| | Sulfones | 1 | 2013 | 127 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1563 | 0.090 |
Why?
| | Glycine | 1 | 2013 | 187 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1462 | 0.090 |
Why?
| | Exercise | 1 | 2023 | 2201 | 0.090 |
Why?
| | Gene Components | 1 | 2011 | 6 | 0.080 |
Why?
| | Genome, Helminth | 1 | 2010 | 3 | 0.080 |
Why?
| | RNA, Spliced Leader | 1 | 2010 | 12 | 0.080 |
Why?
| | RNA Splice Sites | 1 | 2011 | 50 | 0.080 |
Why?
| | Transcriptome | 2 | 2016 | 1046 | 0.080 |
Why?
| | Gastrectomy | 2 | 2024 | 161 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1322 | 0.080 |
Why?
| | Biomarkers | 2 | 2019 | 4275 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2013 | 499 | 0.080 |
Why?
| | Stem Cells | 1 | 2014 | 627 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2020 | 381 | 0.080 |
Why?
| | RNA Splicing | 1 | 2010 | 285 | 0.070 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1718 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 983 | 0.070 |
Why?
| | Cytokines | 1 | 2016 | 2065 | 0.070 |
Why?
| | DNA Nucleotidyltransferases | 1 | 2008 | 11 | 0.070 |
Why?
| | Signal Transduction | 4 | 2016 | 5233 | 0.070 |
Why?
| | Models, Biological | 1 | 2015 | 1822 | 0.070 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2020 | 140 | 0.070 |
Why?
| | Intestinal Mucosa | 1 | 2013 | 676 | 0.070 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 442 | 0.060 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2931 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 2018 | 919 | 0.060 |
Why?
| | Epithelial Cells | 2 | 2023 | 1126 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2021 | 4155 | 0.060 |
Why?
| | Papillomaviridae | 2 | 2016 | 115 | 0.050 |
Why?
| | Registries | 2 | 2024 | 2385 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 331 | 0.050 |
Why?
| | Demography | 1 | 2024 | 288 | 0.050 |
Why?
| | Cell Cycle Proteins | 2 | 2020 | 629 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1958 | 0.050 |
Why?
| | Cetuximab | 2 | 2013 | 111 | 0.050 |
Why?
| | Phenylbutyrates | 1 | 2022 | 23 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 451 | 0.040 |
Why?
| | Physical Fitness | 1 | 2023 | 209 | 0.040 |
Why?
| | Antigens, CD | 2 | 2016 | 555 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 264 | 0.040 |
Why?
| | Organoids | 1 | 2023 | 141 | 0.040 |
Why?
| | Life Style | 1 | 2023 | 479 | 0.040 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 23 | 0.040 |
Why?
| | Feedback, Physiological | 1 | 2020 | 83 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | Antiemetics | 1 | 2020 | 49 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2020 | 170 | 0.040 |
Why?
| | Heterografts | 1 | 2019 | 144 | 0.040 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2020 | 124 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 473 | 0.040 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 208 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 239 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2022 | 5997 | 0.030 |
Why?
| | Acetaminophen | 1 | 2020 | 264 | 0.030 |
Why?
| | Female | 6 | 2022 | 78376 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 538 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 428 | 0.030 |
Why?
| | DNA Repair | 1 | 2020 | 256 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 509 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2015 | 3415 | 0.030 |
Why?
| | DNA Damage | 1 | 2020 | 430 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2016 | 29 | 0.030 |
Why?
| | Cell Cycle | 1 | 2020 | 597 | 0.030 |
Why?
| | Absorption, Radiation | 1 | 2015 | 3 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2018 | 229 | 0.030 |
Why?
| | Promoter Regions, Genetic | 2 | 2013 | 1258 | 0.030 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2016 | 99 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2016 | 73 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2021 | 11695 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2019 | 1465 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 201 | 0.030 |
Why?
| | Cell Division | 1 | 2016 | 766 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 26 | 0.030 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2014 | 14 | 0.030 |
Why?
| | Weight Loss | 1 | 2020 | 837 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 36 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 1135 | 0.030 |
Why?
| | Mutation | 2 | 2018 | 4099 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 339 | 0.030 |
Why?
| | Cross-Priming | 1 | 2013 | 16 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2013 | 22 | 0.030 |
Why?
| | Receptors, Chemokine | 1 | 2013 | 47 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2013 | 60 | 0.030 |
Why?
| | Antigens, CD1 | 1 | 2013 | 60 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3164 | 0.030 |
Why?
| | Mice, SCID | 1 | 2014 | 369 | 0.020 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.020 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 21 | 0.020 |
Why?
| | Gonanes | 1 | 2013 | 28 | 0.020 |
Why?
| | Integrins | 1 | 2013 | 90 | 0.020 |
Why?
| | Male | 4 | 2022 | 72406 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 294 | 0.020 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 35 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 241 | 0.020 |
Why?
| | 5' Untranslated Regions | 1 | 2013 | 59 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1141 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 167 | 0.020 |
Why?
| | Molecular Sequence Annotation | 1 | 2013 | 105 | 0.020 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 109 | 0.020 |
Why?
| | Th17 Cells | 1 | 2013 | 101 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 321 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2014 | 220 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2013 | 245 | 0.020 |
Why?
| | Organ Specificity | 1 | 2013 | 313 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2013 | 521 | 0.020 |
Why?
| | Fetal Blood | 1 | 2014 | 342 | 0.020 |
Why?
| | Gene Silencing | 1 | 2013 | 205 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2438 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 375 | 0.020 |
Why?
| | Glycoproteins | 1 | 2013 | 355 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 758 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 852 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2609 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 682 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 1026 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1786 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1990 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2013 | 389 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3676 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1187 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2852 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 2430 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2013 | 824 | 0.020 |
Why?
| | Aged | 2 | 2021 | 25947 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 623 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1173 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5872 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 345 | 0.020 |
Why?
| | Tetanus Toxin | 1 | 2008 | 6 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2185 | 0.020 |
Why?
| | Computational Biology | 1 | 2013 | 681 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 35928 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1839 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 883 | 0.020 |
Why?
| | Heat-Shock Response | 1 | 2008 | 78 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2008 | 250 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2008 | 185 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 512 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 2008 | 205 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2008 | 405 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1742 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2008 | 383 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2197 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 17101 | 0.010 |
Why?
| | Adult | 1 | 2014 | 40506 | 0.010 |
Why?
|
|
Morton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|